---
created: 2025-04-13
updated: 2025-04-13T10:53
id: gC>p?R@f6h
specialty: patho
specialty_id: 132
tags:
  - source/ak-original-decks::step-1::zanki-step-decks::zanki-immunology-+-general-pathology::pathoma-chapter-3-(neoplasia)
  - "source/ak-step1-v11:": 
  - theme/firstaid::04-pathology::03-neoplasia::14-p-glycoprotein
  - "source/ak-step1-v11:": 
  - theme/nbme::26
  - "source/ak-step1-v11:": 
  - source/ome-banner
  - "source/ak-step1-v11:": 
  - theme/pathoma::03-neoplasia::01-neoplasia::bg-extras
  - "source/ak-step1-v11:": 
  - theme/pathoma::03-neoplasia-alt-tagging::bluegalaxies::extra
  - "source/ak-step1-v11:": 
  - theme/pixorize::03-pharm::11-oncology::doxorubicin,-daunorubicin
  - "source/ak-step1-v11:": 
  - theme/uworld::1000-9999::1000-1999::1819
  - "source/ak-step1-v11:": 
  - theme/uworld::10000-99999::18000-18999::18419
  - source/ak-step1-v11::^other::^expn::bgadd
  - source/ak-step1-v11::^other::^fa-updates::fa2018
type: flashcard
---

# Question
The P-glycoprotein is a(n) **ATP**-dependent **efflux** pump that tumors can produce to generate chemotherapeutic resistance by decreasing intracellular concentration of the drugs

---

# Answer
This actively removes chemotherapeutic agents (particularly hydrophobic agents like the anthracyclines)